[Prospects for the vaccinal prevention of Haemophilus influenzae type b meningitis].
Haemophilus influenzae type b remains the major cause of bacterial meningitis in infants and children. Serum antibodies against the capsular polysaccharide--polyribosylribitolphosphate (PRP)--are protective, but its immunogenicity is poor in children under two years of age. Clinical trials actually in progress concerning an association of PRP with Bordetella pertussis are presented. Other vaccinal preparations are possible, such outer membrane protein, but prospects offered by polysaccharide-protein conjugates appear as the most encouraging.
D000907:Antibodies, Bacterial / Q000032:analysis; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004306:Dose-Response Relationship, Immunologic; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008583:Meningitis, Haemophilus / Q000517:prevention & control*; D011134:Polysaccharides / Q000276:immunology
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D011134:Polysaccharides; C008984:polyribitol phosphate
Perspectives dans la prévention vaccinale des méningites a Haemophilus influenzae type b.